NK:IO

What NK:IO does

NK:IO is a preclinical biotechnology company developing natural killer (NK) cell-based immunotherapies for cancer, with an initial focus on ovarian cancer and broader ambition across haematological and solid tumours. Founded in December 2020 as a spinout from Imperial College London, the company is built on pioneering discoveries in NK cell biology from Professors Hugh Brady (Immunology, Imperial) and Matthew Fuchter (Chemistry, Oxford), combined with operational leadership from co-founder Mike Romanos and CEO Richard Hopkins.

The company operates three interrelated proprietary platforms. wNK:IO Cells are first-generation human NK cells derived from umbilical cord blood stem cells using a synergistic combination of a small molecule antagonist and recombinant protein ligand, producing highly functional cells that avoid the exhaustion phenotype that limits competitor NK technologies. eNK:IO Cells are next-generation engineered NK cells produced by deleting inhibitory receptors prior to differentiation, yielding enhanced cytotoxic and tumour cell-sensing properties for hard-to-treat cancer subtypes. dNK:IO REV-ERB Antagonists are small molecules that mobilise and enhance NK cell production in vivo, enabling on-demand NK cell expansion with potential implications beyond oncology.

NK:IO does not yet generate revenue. Its business model is centred on preclinical development through to licensing, partnership, or acquisition by pharmaceutical companies, with eventual commercialization through oncology treatment centres. Operations are funded by approximately £5.1M of seed capital, comprising £3.2M in equity led by Cancer Research Horizons and £1.9M in Innovate UK grants, with manufacturing process development conducted in collaboration with the Cell and Gene Therapy Catapult.

Name

NK:IO

Legal name

NK:IO Limited

Website

https://nk-io.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

NK:IO is a preclinical biotech spinout from Imperial College London developing NK cell-based immunotherapies for cancer, with three proprietary platforms (wNK:IO, eNK:IO, dNK:IO) targeting solid and haematological tumours, initially ovarian cancer.

Ownership category

akta.pro rank

Product category

Cell Therapy / Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

Keywords

• NK cell therapy
• Cancer immunotherapy
• Cell therapy platform
• Small molecule oncology
• Solid tumor treatment

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cell Therapy Development and Commercialization: As a preclinical biotech company, NK:IO does not yet generate revenue. The company is developing NK cell therapy candidates targeting solid tumors (initially ovarian cancer). Future revenue is expected to come from licensing, partnerships with pharmaceutical companies, and potentially direct commercialization of cell therapy products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

NK:IO is a preclinical-stage biotechnology company developing NK (Natural Killer) cell-based immunotherapies and small molecule oncology drugs targeting haematological and solid tumours, with an initial focus on ovarian cancer. The company operates three interrelated proprietary technology platforms (wNK:IO cells, eNK:IO cells, and dNK:IO REV-ERB antagonists) that address the two fundamental barriers limiting NK cell therapy: inability to expand NK cells at scale and rapid exhaustion of cytotoxic activity. The platform is built on pioneering discoveries in NK cell biology from Imperial College London researchers.

Product overview

NK:IO is developing a portfolio of NK cell therapy platforms and small molecule candidates targeting both haematological and solid tumours. The company's three interrelated proprietary technology platforms include: wNK:IO Cells (first-generation NK cells derived from umbilical cord blood with enhanced expansion), eNK:IO Cells (next-generation engineered NK cells with enhanced cytotoxic properties), and dNK:IO REV-ERB Antagonists (small molecules for in vivo NK cell production). The lead indication is ovarian cancer, with the company at research/early preclinical stage of development.

Differentiator

Problem solved

Functional benefit

Products and services

• wNK:IO Cells

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Cell and Gene Therapy CatapultcoreStrategic or Co-development Partner · 11 July 2023The £1.6M Innovate UK grant supports preclinical development including development of a manufacturing process in collaboration with the Cell and Gene Therapy Catapult. The Catapult's mission is to support the UK's cell and gene therapy industry.
• Imperial College LondoncoreStrategic or Co-development PartnerNK:IO is a spinout from Imperial College London based on pioneering discoveries in NK cell biology from Professor Hugh Brady and Professor Matthew Fuchter.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Fate Therapeutics: Clinical-stage US biotech pioneering iPSC-derived NK cell and T-cell therapies with off-the-shelf, multiplexed engineering — directly comparable in modality, off-the-shelf thesis, and engineered NK cell approach.
• Cytovia Therapeutics: Clinical-stage biotech developing iPSC-derived NK cells and NK-engaging antibodies for haematological malignancies and solid tumours — a direct NK cell therapy peer with overlapping tumour focus.
• Nkarta Therapeutics: Clinical-stage US biotech developing engineered NK cell therapies (chimeric antigen receptor and off-the-shelf allogeneic NK) for haematological and solid tumours — a direct competitor targeting the same NK cell modality and tumour settings as NK:IO.
• Shoreline Biosciences: Clinical-stage biotech developing iPSC-derived NK cell therapies for cancer, with multiple pharma partnerships — a direct NK cell therapy peer with a comparable partnership-driven business model.
• Century Therapeutics: Clinical-stage US biotech developing iPSC-derived allogeneic NK and T cell therapies with engineered resistance to the tumour microenvironment — directly comparable as an engineered cell therapy peer with a similar solid-tumour ambition.

Emerging players

• Glycostem: Clinical-stage Dutch biotech developing off-the-shelf NK cell therapies (oNKord) from umbilical cord blood — directly comparable in cord-blood-derived NK cell sourcing, similar to NK:IO's wNK:IO platform.
• Indapta Therapeutics: Early-stage US biotech developing off-the-shelf NK cell therapies using a subset of NK cells (g-NK) with enhanced cytotoxicity — emerging peer in the engineered NK cell space.
• Catamaran Bio: Emerging clinical-stage biotech engineering off-the-shelf NK cell therapies using CAR-NK and synthetic biology — narrower in scope but a near-direct competitor in engineered NK cell therapy.

Broad incumbents

• Innate Pharma: Larger, clinical-stage French biotech with a broad innate immunity pipeline including NK cell engagers, monoclonal antibodies, and cell therapy programmes — a broad incumbent in NK cell biology and oncology immunotherapy.
• bit.bio: UK-based cell therapy company developing iPSC-derived cell therapies (including NK and T cells) using a proprietary coding platform — a UK cell therapy peer and the prior employer of NK:IO's CEO, providing both competitive overlap and ecosystem relevance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nk-io

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NK:IO